An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Esperion (ESPR) will report its first quarter 2024 financial results on May 7, 2024. The company aims to improve outcomes for patients with cardiovascular and cardiometabolic diseases by developing innovative medicines to reduce LDL-cholesterol levels.
Esperion (ESPR) pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024. L'azienda mira a migliorare i risultati per i pazienti affetti da malattie cardiovascolari e cardiometaboliche, sviluppando nuovi farmaci per ridurre i livelli di colesterolo LDL.
Esperion (ESPR) reportará sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La compañía tiene como objetivo mejorar los resultados para pacientes con enfermedades cardiovasculares y cardiometabólicas mediante el desarrollo de medicinas innovadoras para reducir los niveles de colesterol LDL.
에스페리온(ESPR)은 2024년 5월 7일에 2024년 첫 분기 재무 결과를 보고할 예정입니다. 이 회사는 심혈관 및 심장대사 질환을 앓고 있는 환자들의 결과를 개선하기 위해 LDL 콜레스테롤 수치를 낮추는 혁신적인 약물을 개발함으로써 목표를 두고 있습니다.
Esperion (ESPR) publiera ses résultats financiers du premier trimestre 2024 le 7 mai 2024. L'entreprise vise à améliorer les résultats pour les patients souffrant de maladies cardiovasculaires et cardiometaboliques en développant des médicaments innovants pour réduire les niveaux de cholestérol LDL.
Esperion (ESPR) wird am 7. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen zielt darauf ab, die Ergebnisse für Patienten mit kardiovaskulären und kardiometabolischen Erkrankungen zu verbessern, indem es innovative Medikamente zur Senkung des LDL-Cholesterinspiegels entwickelt.
Positive
None.
Negative
None.
ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
